Literature DB >> 15355914

Favorable neuroblastoma genes and molecular therapeutics of neuroblastoma.

Xao X Tang1, Marjorie E Robinson, Justin S Riceberg, David Y Kim, Bing Kung, Tracy B Titus, Satoshi Hayashi, Alan W Flake, David Carpentieri, Naohiko Ikegaki.   

Abstract

PURPOSE AND EXPERIMENTAL
DESIGN: Neuroblastoma (NB) is a common pediatric solid tumor that exhibits a striking clinical bipolarity: favorable and unfavorable. Favorable NB genes (EPHB6, EFNB2, EFNB3, NTRK1, and CD44) are genes whose high-level expression predicts favorable NB outcome, and forced expression of these genes inhibits growth of unfavorable NB cells. In this study, we investigated whether favorable NB gene expression could be augmented in unfavorable NB cells by chemical compounds and whether an increased expression of these genes was associated with suppression of NB growth and metastasis.
RESULTS: We found that inhibitors of DNA methylation [5-aza-2'-deoxycytidine (5AdC)], histone deacetylase (HDAC) [4-phenylbutyrate (4PB)], and proteasome (MG262) enhanced the expression of favorable NB genes in NB cell lines and inhibited the growth of these cells in vitro (P < 0.0005). The growth-inhibitory effects of 5AdC and 4PB in vitro were in part due to caspase-dependent cell death and inhibition of DNA synthesis. Administration of 5AdC and/or 4PB also suppressed growth of subcutaneous NB xenografts in nude mice (P < 0.001), which was accompanied by enhanced favorable NB gene expression and an increase in apoptosis. Moreover, 4PB suppressed bone marrow and liver metastases of NB cells in severe combined immunodeficient/Beige mice (P = 0.007 and P = 0.008, respectively). The growth-suppressive activity of HDAC inhibitors on NB was further confirmed by the efficacy of trichostatin A, a potent and specific HDAC inhibitor.
CONCLUSIONS: Collectively, these observations further emphasize the link between the elevated favorable NB gene expression and a benign phenotype of NB.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15355914     DOI: 10.1158/1078-0432.CCR-04-0395

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  23 in total

1.  Negative and positive regulation of gene expression by mouse histone deacetylase 1.

Authors:  Gordin Zupkovitz; Julia Tischler; Markus Posch; Iwona Sadzak; Katrin Ramsauer; Gerda Egger; Reinhard Grausenburger; Norbert Schweifer; Susanna Chiocca; Thomas Decker; Christian Seiser
Journal:  Mol Cell Biol       Date:  2006-08-28       Impact factor: 4.272

2.  Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.

Authors:  Jaime Torres; Paul L Regan; Robby Edo; Payton Leonhardt; Eric I Jeng; Eric F Rappaport; Naohiko Ikegaki; Xao X Tang
Journal:  Int J Oncol       Date:  2010-10       Impact factor: 5.650

3.  Neuroblastoma cells negative for CD44 possess tumor-initiating properties.

Authors:  Elena K Siapati; Erasmia Rouka; Despina Kyriakou; George Vassilopoulos
Journal:  Cell Oncol (Dordr)       Date:  2011-03-22       Impact factor: 6.730

4.  Combined Treatments with a Retinoid Receptor Agonist and Epigenetic Modulators in Human Neuroblastoma Cells.

Authors:  Viviane Rösner Almeida; Igor Araujo Vieira; Marienela Buendia; André Tesainer Brunetto; Lauro J Gregianin; Algemir Lunardi Brunetto; Fábio Klamt; Caroline Brunetto de Farias; Ana Lucia Abujamra; Patrícia Luciana da Costa Lopez; Rafael Roesler
Journal:  Mol Neurobiol       Date:  2016-11-10       Impact factor: 5.590

5.  Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.

Authors:  Paul L Regan; Joshua Jacobs; Gerald Wang; Jaime Torres; Robby Edo; Jennifer Friedmann; Xao X Tang
Journal:  Int J Oncol       Date:  2011-01       Impact factor: 5.650

6.  Histone deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural progenitor cells.

Authors:  Jenny Hsieh; Kinichi Nakashima; Tomoko Kuwabara; Eunice Mejia; Fred H Gage
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-10       Impact factor: 11.205

7.  Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin.

Authors:  Yuting Kuang; Anthony El-Khoueiry; Pietro Taverna; Mats Ljungman; Nouri Neamati
Journal:  Mol Oncol       Date:  2015-06-16       Impact factor: 6.603

8.  Removing intensity effects and identifying significant genes for Affymetrix arrays in macrophage migration inhibitory factor-suppressed neuroblastoma cells.

Authors:  Jianqing Fan; Yongxiong Chen; Hiu Man Chan; Paul K H Tam; Yi Ren
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-28       Impact factor: 11.205

9.  HDAC6 regulates neuroblastoma cell migration and may play a role in the invasion process.

Authors:  Linlin Zhang; Ningning Liu; Songbo Xie; Xianfei He; Jun Zhou; Min Liu; Dengwen Li
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

10.  Transient treatment with epigenetic modifiers yields stable neuroblastoma stem cells resembling aggressive large-cell neuroblastomas.

Authors:  Naohiko Ikegaki; Hiroyuki Shimada; Autumn M Fox; Paul L Regan; Joshua R Jacobs; Sakeenah L Hicks; Eric F Rappaport; Xao X Tang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.